東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁 到查詢結果 [ null ]

切換: 標籤 | MARC模式 | ISBD

Surface-Engineered Exosomes for Targ...

Pathrikar, Tanvi Vinod,

FindBook

Google Book

Amazon

博客來

Surface-Engineered Exosomes for Targeted Drug and Gene Delivery to Cartilage /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Surface-Engineered Exosomes for Targeted Drug and Gene Delivery to Cartilage // Tanvi Vinod Pathrikar.
作者:	Pathrikar, Tanvi Vinod,
面頁冊數:	1 electronic resource (141 pages)
附註:	Source: Dissertations Abstracts International, Volume: 86-06, Section: B.
Contained By:	Dissertations Abstracts International86-06B.
標題:	Bioengineering. -
電子資源:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31761090
ISBN:	9798346866862

Surface-Engineered Exosomes for Targeted Drug and Gene Delivery to Cartilage /
Pathrikar, Tanvi Vinod,

Surface-Engineered Exosomes for Targeted Drug and Gene Delivery to Cartilage /Tanvi Vinod Pathrikar. - 1 electronic resource (141 pages)

Source: Dissertations Abstracts International, Volume: 86-06, Section: B.

Osteoarthritis (OA) is a degenerative joint disease that affects multiple joint tissues and is a leading cause of pain and disability worldwide, yet it remains without a cure. Although several disease-modifying OA drugs (DMOADs) have been identified, they have largely failed in clinical trials. The dense, avascular, and negatively charged cartilage extracellular matrix (ECM), combined with the rapid clearance of therapeutic agents from the synovial joint space, presents significant challenges for the efficient transport and sustained delivery of drugs to chondrocytes embedded deep within the tissue. Exosomes, nanoscale extracellular vesicles secreted by cells, have emerged as promising vehicles for drug delivery due to their non-immunogenic properties and role in intercellular communication. However, exosomes have a negative surface charge due to their lipid bilayer which is repelled by the anionic cartilage matrix. This doctoral thesis addresses these challenges by developing surface-engineered, cartilage-targeting exosomes as non-viral carriers for gene therapy and drug delivery in OA. In the first aim, exosomes are surface-engineered by anchoring optimally charged, cartilage-targeting arginine-rich motifs onto the anionic exosome bilayer, utilizing buffer pH as a charge-reversal mechanism. When intra-articularly injected into destabilized medial meniscus mice knees with early-stage OA, these engineered exosomes demonstrated the ability to penetrate the full thickness of the cartilage.Receptor antagonist of Interleukin-1 (IL-1RA) prevents the activation of catabolic pathways triggered by Interleukin-1 in OA. In the second aim, the surface-engineered exosomes are modified by loading them with IL-1RA to target highly negatively charged cartilage tissue, forming intra-cartilage depots for sustained IL-1RA delivery. By anchoring cartilage-targeting cationic motifs onto bovine milk-derived exosomes and loading IL-1RA on both the surface and within the exosomes, the formulations effectively penetrated and were retained in the full thickness of early-stage arthritic cartilage. These formulations significantly suppressed cytokine-induced catabolism with a single dose. Finally, gene therapy holds promise for cartilage repair in osteoarthritis (OA) by programming the cells to express the disease-modifying molecules endogenously. Viral vector-mediated gene delivery has shown potential to a greater extent but is limited by concerns over immunogenicity and cytotoxicity. To address these challenges, aim three explores the applicability of surface-engineered exosomes as non-viral carriers for gene therapy in OA. These engineered exosomes efficiently delivered encapsulated eGFP and IL-1RA mRNA to chondrocytes in deep tissue layers. In destabilized medial meniscus mouse models with early-stage OA, intra-articular injection of eGFP mRNA-loaded engineered exosomes overcame joint clearance, penetrated cartilage, created an intra-tissue depot, and expressed eGFP effectively, whereas native exosomes did not. This suggests strong translational potential for these engineered exosomes as a platform technology for cartilage-targeted non-viral delivery of therapeutic mRNA for OA treatment.In conclusion, these findings demonstrate the potential of surface-engineered exosomes as a cell-free platform for sustained OA drug delivery. The engineered exosome formulations effectively delivered IL-1RA and IL-1RA mRNA, successfully targeting early-stage arthritic cartilage and offering a promising approach to improving localized therapeutic efficacy in OA treatment.

English

ISBN: 9798346866862Subjects--Topical Terms:

657580
Bioengineering.
Subjects--Index Terms:

Gene delivery

Surface-Engineered Exosomes for Targeted Drug and Gene Delivery to Cartilage /
LDR:05108nmm a22004573i 4500 001 2437543
005 20251124054802.5
006 m o d
007 cr|nu||||||||
008 261011s2024 miu||||||m |||||||eng d
020 $a 9798346866862
035 $a (MiAaPQD)AAI31761090
035 $a AAI31761090
040 $a MiAaPQD $b eng $c MiAaPQD $e rda
100 1 $a Pathrikar, Tanvi Vinod, $e author. $3 3828564
245 1 0 $a Surface-Engineered Exosomes for Targeted Drug and Gene Delivery to Cartilage / $c Tanvi Vinod Pathrikar.
264 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2024
300 $a 1 electronic resource (141 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 86-06, Section: B.
500 $a Includes supplementary digital materials.
500 $a Advisors: Bajpayee, Ambika G. Committee members: Ionescu, Andreia; Amiji, Mansoor.
502 $b Ph.D. $c Northeastern University $d 2024.
520 $a Osteoarthritis (OA) is a degenerative joint disease that affects multiple joint tissues and is a leading cause of pain and disability worldwide, yet it remains without a cure. Although several disease-modifying OA drugs (DMOADs) have been identified, they have largely failed in clinical trials. The dense, avascular, and negatively charged cartilage extracellular matrix (ECM), combined with the rapid clearance of therapeutic agents from the synovial joint space, presents significant challenges for the efficient transport and sustained delivery of drugs to chondrocytes embedded deep within the tissue. Exosomes, nanoscale extracellular vesicles secreted by cells, have emerged as promising vehicles for drug delivery due to their non-immunogenic properties and role in intercellular communication. However, exosomes have a negative surface charge due to their lipid bilayer which is repelled by the anionic cartilage matrix. This doctoral thesis addresses these challenges by developing surface-engineered, cartilage-targeting exosomes as non-viral carriers for gene therapy and drug delivery in OA. In the first aim, exosomes are surface-engineered by anchoring optimally charged, cartilage-targeting arginine-rich motifs onto the anionic exosome bilayer, utilizing buffer pH as a charge-reversal mechanism. When intra-articularly injected into destabilized medial meniscus mice knees with early-stage OA, these engineered exosomes demonstrated the ability to penetrate the full thickness of the cartilage.Receptor antagonist of Interleukin-1 (IL-1RA) prevents the activation of catabolic pathways triggered by Interleukin-1 in OA. In the second aim, the surface-engineered exosomes are modified by loading them with IL-1RA to target highly negatively charged cartilage tissue, forming intra-cartilage depots for sustained IL-1RA delivery. By anchoring cartilage-targeting cationic motifs onto bovine milk-derived exosomes and loading IL-1RA on both the surface and within the exosomes, the formulations effectively penetrated and were retained in the full thickness of early-stage arthritic cartilage. These formulations significantly suppressed cytokine-induced catabolism with a single dose. Finally, gene therapy holds promise for cartilage repair in osteoarthritis (OA) by programming the cells to express the disease-modifying molecules endogenously. Viral vector-mediated gene delivery has shown potential to a greater extent but is limited by concerns over immunogenicity and cytotoxicity. To address these challenges, aim three explores the applicability of surface-engineered exosomes as non-viral carriers for gene therapy in OA. These engineered exosomes efficiently delivered encapsulated eGFP and IL-1RA mRNA to chondrocytes in deep tissue layers. In destabilized medial meniscus mouse models with early-stage OA, intra-articular injection of eGFP mRNA-loaded engineered exosomes overcame joint clearance, penetrated cartilage, created an intra-tissue depot, and expressed eGFP effectively, whereas native exosomes did not. This suggests strong translational potential for these engineered exosomes as a platform technology for cartilage-targeted non-viral delivery of therapeutic mRNA for OA treatment.In conclusion, these findings demonstrate the potential of surface-engineered exosomes as a cell-free platform for sustained OA drug delivery. The engineered exosome formulations effectively delivered IL-1RA and IL-1RA mRNA, successfully targeting early-stage arthritic cartilage and offering a promising approach to improving localized therapeutic efficacy in OA treatment.
546 $a English
590 $a School code: 0160
650 4 $a Bioengineering. $3 657580
650 4 $a Pharmacology. $3 634543
650 4 $a Genetics. $3 530508
650 4 $a Immunology. $3 611031
653 $a Gene delivery
653 $a Targeted drug
653 $a Osteoarthritis
653 $a Exosomes
653 $a Arthritic cartilage
690 $a 0202
690 $a 0419
690 $a 0982
690 $a 0369
710 2 $a Northeastern University. $b Bioengineering. $e degree granting institution. $3 3828565
720 1 $a Bajpayee, Ambika G. $e degree supervisor.
773 0 $t Dissertations Abstracts International $g 86-06B.
790 $a 0160
791 $a Ph.D.
792 $a 2024
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31761090